Antenatal Multiple Micronutrient Supplementation (MMS) in Indonesia

Launched by JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH · Jan 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to effectively provide multiple micronutrient supplements (MMS) to pregnant women in Indonesia. The goal is to see if these supplements can improve the nutrition of mothers and the health of their babies. Researchers will look at different ways to deliver these supplements and how to encourage pregnant women to take them regularly. They want to understand how well the program works and how it can fit into existing healthcare services for expectant mothers.

To participate in this study, pregnant women must be enrolled in antenatal care through government health facilities and receive MMS before 20 weeks of pregnancy. They should also be willing to consent to the study. Women who have serious pregnancy complications or plan to move away during the study will not be eligible. Participants can expect to receive guidance on taking the supplements and may be asked to share their experiences in interviews. This research is important because it aims to ensure that more mothers and their babies can benefit from better nutrition during pregnancy.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria for 3,360 pregnant women (PW) enrolled from 8 high-intensity evaluation districts (sample group 1)
• • Enrolled in ANC 1 through government health facilities.
• • Received MMS at ANC 1
• • Gestational age at ANC 1 ≤ 20 weeks (verified by health professionals)
• • Consent provided to participate in the study.
• • Exclusion Criteria for 3,360 pregnant women (PW) enrolled from 8 high-intensity evaluation districts (sample group 1)
• • PW with complicated pregnancy complications (e.g., thalassemia, hemochromatosis,)
• • PW planning to move outside study district during study period.
• • Inclusion Criteria for 72 PW / recently delivered women participating in in-depth interviews (IDI) only (sample group 2)
• • Enrolled in ANC 1 through government health facilities.
• • Received MMS at ANC 1
• • Gestational age at ANC 1 ≤ 20 weeks (verified by health professionals)
• • Consent provided to participate in qualitative component of study.
• • Received MMS for at least 3 months.
• • Attended \> 2 ANC visits.
• • \< 4 weeks post-partum
• • Exclusion Criteria for 72 PW / recently delivered women participating in in-depth interviews (IDI) only (sample group 2)
• • Enrolled in Sample 1
• • Women who are more than 4 weeks postpartum.
• • Inclusion Criteria for 180 healthcare providers participating in focus group discussions (FGDs) (sample group 3)
• • Government health workers who provide ANC services (e.g., midwives, general practitioners, and nutritionists)
• • Government health facility management staff (e.g., Head of Puskesmas Community Health Clinic, Coordinating Midwife, Head of Pharmacy)
• • Willing to give consent to participate in the FGD.
• • Exclusion Criteria for 180 healthcare providers participating in FGDs (sample group 3) • Healthcare Providers who have already participated in a FGD will not be eligible to participate in another FGD
• • Inclusion Criteria for 76 government decision-makers participating in FGD or IDI (sample group 4)
• • District-, provincial-, or national-level decision-makers working in nutrition, maternal, newborn and child health, or pharmaceutical roles associated with the antenatal care system in Indonesia.
• • Willing to give consent to participate in the FGD or IDI.
• • Exclusion Criteria for 76 government decision-makers participating in FGD or IDI (sample group 4)
• • • None